A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
A phase 1/2 trial of DYP688 in uveal melanoma, run by Novartis Pharmaceuticals, active and no longer recruiting.
Overview
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas is a phase 1/2 interventional study registered as NCT05415072 by Novartis Pharmaceuticals, with 66 participants enrolled, started 2022-07-04 and due to reach its primary completion in 2027-10-01. Interventions recorded: DYP688.
Similar pages
not linked directly; found by shared links- TrialEvaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
Shares Uveal melanoma and the tag pipeline.
- TrialA Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialA Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialA Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialAn Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialStudy of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialRibociclib (LEE011) Rollover Study for Continued Access
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialStudy to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.